cannabidiol extract (University of Mississippi)

A hemp-derived cannabidiol (CBD) oral solution developed by the University of Mississippi's National Center for Natural Products Research (NCNPR). This specific formulation is a non-psychoactive cannabinoid extract containing less than 0.3% Delta-9-tetrahydrocannabinol (THC), prepared under FDA Current Good Manufacturing Practices at the Coy Waller Laboratory. It is primarily investigated for the treatment of refractory epilepsy in pediatric patients (aged 5-19) as an adjunct to standard antiepileptic drugs. The drug's mechanism of action involves the modulation of multiple signaling pathways, including the antagonism of GPR55 and the desensitization of TRPV1 channels, which collectively reduce neuronal hyperexcitability without direct activation of CB1 or CB2 receptors. The University of Mississippi Medical Center (UMMC) has conducted clinical trials under FDA compassionate use and pharmacokinetic studies in healthy adults to inform dosing and safety profiles.

Other names

CBD Cannabis Extract Oral SolutionCBD oral solutioncannabidiol extract